

the **DBL** report

Issue #67, May 2012

An Official Accompaniment to the Alberta Health and Wellness Drug Benefit List (AHWDBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

EXPERT COMMITTEE MEMBERS:

James L. Silvius, BA, MD, FRCPC (Chair)
Robert J. Herman, MD, FRCPC (Vice-Chair)
Margaret Barr, BSc (Pharm)
Jeffrey A. Johnson, BSP, MSc, PhD
Saibal Nandy MBBS, MRCPsych, FRCPC
Glen J. Pearson, BScPhm, PharmD, FCSHP
Cheryl A. Sadowski, BSc (Pharm), PharmD, FCSHP
Kelly B. Zarnke, MD, MSc, FRCPC

ALBERTA HEALTH AND WELLNESS LIAISONS:

Steve Long, BSc (Pharm), MBA
Mark Harasymuk, BSc (Pharm)

ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Sherry Dieleman, BSc (Pharm), MSc
Micheal S. Guirguis, BSc (Pharm), PhD
Rhonda Shkrobot, BSc (Pharm)
Carlyn Volume-Smith, BSc (Pharm), MSc, PhD

In this issue:

- *Brief Summary of Drug Review Activities*
- *Products Originally Reviewed via the Common Drug Review (CDR)*
- *Highlights of New IC Groupings*
- *Other Products added to the AHWDBL*

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on March 15, 2012. The Committee reviewed Manufacturer submissions for 52 Drug Products for potential listing or change in listing status on the AHWDBL.

In addition to these Drug Products, 119 generic Drug Products underwent Expedited Review for listing on the AHWDBL effective May 1, 2012.

The following are highlights of recent changes to the AHWDBL. A complete list of changes and the full AHWDBL can be found at <https://www.ab.bluecross.ca/dbl/publications.html>.

Products Originally Reviewed via the Common Drug Review (CDR)

In keeping with the recommendations from the CDR, the following Drug Products have not been added to the AHWDBL:

- **ONSOLIS** (fentanyl) (MED) 200 mcg, 400 mcg, 600 mcg, 800 mcg & 1200 mcg buccal soluble films
- **TARGIN** (oxycodone HCL/ naloxone HCL) (PUR) 10 mg/ 5 mg, 20 mg/10 mg & 40 mg/ 20 mg extended release tablets

A complete list of changes, as well as the full AHWDBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

Please refer to the current AHWDBL for explanations of coverage, including a listing of coverage criteria (where applicable).

Other Products Added to the AHW DBL

TRAJENTA (linagliptin) (BOE) **5 mg tablet** was reviewed via the CDR process. **TRAJENTA** is indicated in adult patients with type 2 diabetes mellitus (T2DM) to improve glycaemic control. In keeping with the recommendations from the CDR, this Drug Product has been added to the *AHWDBL* with a listing via Step Therapy/Special Authorization. Please refer to the current *AHWDBL* for a full listing of coverage criteria.

JANUVIA (sitagliptin phosphate monohydrate) (MFC) **100 mg tablet** and **JANUMET** (sitagliptin phosphate monohydrate/ metformin HCl) (MFC) **50 mg/ 500 mg, 50 mg/ 850 mg and 50 mg/100 mg tablets** were reviewed via the CDR process. **JANUVIA** and **JANUMET** are indicated in adult patients with type 2 diabetes mellitus (T2DM) to improve glycaemic control. In keeping with the recommendations from the CDR, these Drug Products have been added to the *AHWDBL* with a listing via Step Therapy/Special Authorization. Please refer to the current *AHWDBL* for a full listing of coverage criteria.

PRADAX (dabigatran etexilate) (BOE) **110 mg and 150 mg capsule** were reviewed via the CDR process. **PRADAX** will be available to at-risk patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism. Further, anticoagulation must be inadequate following a reasonable trial on warfarin or warfarin is contraindicated or not possible due to inability to regularly monitor the patient's INR. These Drug Products have been added to the *AHWDBL* with a listing via Step Therapy/Special Authorization. Please refer to the *AHWDBL* for a full listing of coverage criteria.

Highlights of New Interchangeable (IC) Groupings

The recent additions of the following Drug Products to the *AHWDBL* have resulted in the creation of New IC Groupings, effective May 1, 2012:

- **ENTACAPONE 200 mg tablet**
 - **APO-ENTACAPONE (APX)**
 - **TEVA-ENTACAPONE (TEV)**
- **LOSARTAN POTASSIUM 25 mg, 50 mg & 100 mg tablets**
 - **APO-LOSARTAN (APX)**
 - **CO LOSARTAN (COB)**
 - **MYLAN-LOSARTAN (MYP)**
 - **PMS-LOSARTAN (PMS)**
 - **SANDOZ LOSARTAN (SDZ)**
 - **TEVA-LOSARTAN (TEV)**
- **LOSARTAN POTASSIUM/ HYDROCHLOROTHIAZIDE 50 mg/12.5 mg, 100 mg/12.5 mg & 100/25 mg tablets**
 - **APO-LOSARTAN/HCTZ (APX)**
 - **MYLAN-LOSARTAN HCTZ (MYP)**
 - **SANDOZ LOSARTAN HCT (SDZ)**
 - **SANDOZ LOSARTAN HCT DS (SDZ) (100 mg/25 mg tablet only)**
 - **TEVA-LOSARTAN HCT (TEV)**
- **NABILONE 0.5 mg & 1 mg capsules**
 - **PMS-NABILONE (PMS)**
 - **RAN-NABILONE (RAN)**
- **RIZATRIPTAN BENZOATE 5 mg & 10 mg orally disintegrating tablets**
 - **CO RIZATRIPTAN ODT (COB)**
 - **MYLAN-RIZATRIPTAN ODT (MYP)**
 - **SANDOZ RIZATRIPTAN ODT (SDZ)**
- **ROSUVASTATIN CALCIUM 5 mg, 10 mg, 20 mg & 40 mg tablets**
 - **APO-ROSUVASTATIN (APX)**
 - **CO ROSUVASTATIN (COB)**
 - **MYLAN-ROSUVASTATIN (MYP)**
 - **PMS-ROSUVASTATIN (PMS)**
 - **RAN-ROSUVASTATIN (RAN)**
 - **SANDOZ ROSUVASTATIN (SDZ)**
 - **TEVA-ROSUVASTATIN (TEV)**
- **TELMISARTAN 40 mg & 80 mg tablets**
 - **MYLAN-TELMISARTAN (MYP)**
 - **SANDOZ TELMISARTAN (SDZ)**
 - **TEVA-TELMISARTAN (TEV)**
- **TELMISARTAN/HYDROCHLOROTHIAZIDE 80 mg/12.5 mg & 80 mg/25 mg tablets**
 - **MYLAN-TELMISARTAN HCTZ (MYP)**
 - **TEVA-TELMISARTAN HCTZ (TEV)**

A complete list of changes, as well as the full *AHWDBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

*Please refer to the current *AHWDBL* for explanations of coverage, including a listing of coverage criteria (where applicable).*